Company news
Livanova Plc (NASDAQ:LIVN) news
Livanova Plc news releases on 6ix. Latest, Sep 23, 2026: LivaNova to Announce Third-Quarter 2026 Results
Press releases & updates
LivaNova to Announce Third-Quarter 2026 Results
September 23, 2026
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
September 3, 2026
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
August 5, 2026
LivaNova to Announce Second-Quarter 2026 Results
June 24, 2026
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
June 16, 2026
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
June 11, 2026
LivaNova Appoints Anne Liddy as Chief Legal Officer
June 5, 2026
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
May 21, 2026
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
May 18, 2026
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
May 5, 2026
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
April 20, 2026
LivaNova to Announce First-Quarter 2026 Results
March 24, 2026
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
March 18, 2026
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
February 24, 2026
Orrum Announces Strategic Partnership with LivaNova to Unite Intelligent Data with Innovative Perfusion Technology
February 20, 2026
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
January 19, 2026
LivaNova to Present at J.P. Morgan Healthcare Conference in January
December 22, 2025
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
December 2, 2025
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
December 1, 2025
LivaNova to Present at Piper Sandler Healthcare Conference in December
November 24, 2025
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
November 23, 2025
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
November 11, 2025
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
November 4, 2025
LivaNova to Present at Wolfe Research Healthcare Conference in November
October 22, 2025
LivaNova to Announce Third-Quarter 2025 Results
October 7, 2025
LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting
October 6, 2025
LivaNova Appoints Donald Zurbay as a New Director
September 3, 2025
LivaNova to Host Investor Day on November 12, 2025
August 24, 2025
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
August 21, 2025
LivaNova Launches Essenz Perfusion System in China
August 17, 2025
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
August 5, 2025
LivaNova to Announce Second-Quarter 2025 Results
July 8, 2025
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
June 4, 2025
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
June 4, 2025
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
June 3, 2025
LivaNova to Present at the Jefferies Global Healthcare Conference
May 14, 2025
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
May 6, 2025
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
May 6, 2025
LivaNova to Announce First-Quarter 2025 Results
March 25, 2025
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
February 24, 2025
LivaNova to Present at the Barclays Global Healthcare Conference
February 20, 2025
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
January 20, 2025
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
January 5, 2025
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
December 17, 2024
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
December 4, 2024
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
November 13, 2024
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
November 10, 2024
LivaNova Reports Third-Quarter 2024 Results
October 29, 2024
LivaNova Appoints Susan Podlogar as a New Director
October 7, 2024
LivaNova to Announce Third-Quarter 2024 Results
September 24, 2024